| Sermorelin The "gentler," formerly-FDA-approved GH-axis peptide — the best-evidenced option you can still legally get through a compounding pharmacy. | Grade B Real human trials, limited or historical | Compoundable (503A) | green | $96–$225/month (telehealth); $200–$400/month (clinic) | Sermorelin is legally compoundable (503A) thanks to its prior FDA approval as Geref. Human evidence is Grade B — real historical trial data. It is the best-evidenced GH-axis peptide with a legal supervised route today. | See the evidence → |
| BPC-157 The most-hyped, least-human-proven "healing" peptide — extensive rodent data, zero published human trials. | Grade D Animal studies only, unproven in humans | Under FDA review | amber | $350–$900 (clinic-supervised course) | BPC-157 is not FDA-approved and is under FDA review (July 23, 2026 PCAC). Human evidence is Grade D — animal studies only. If you pursue it, wait for the ruling and use a licensed provider, never gray-market vials. | See the evidence → |
| TB-500 The other half of the "wolverine stack" — soft-tissue recovery claims, but only animal data for the fragment actually sold. | Grade D Animal studies only, unproven in humans | Under FDA review | amber | UNKNOWN (usually bundled with BPC-157 courses, ~$350–$900) | TB-500 is not FDA-approved and is under FDA review (July 23, 2026 PCAC). Human evidence is Grade D — the fragment sold to consumers has animal data only. The full-length Tβ4 human trials are a different molecule. | See the evidence → |
| KPV An anti-inflammatory tripeptide studied for gut and skin inflammation — promising in cells and animals, untested in humans. | Grade D Animal studies only, unproven in humans | Under FDA review | amber | UNKNOWN | KPV is not FDA-approved and is under FDA review (July 23, 2026 PCAC). Human evidence is Grade D — cell and animal anti-inflammatory data only, no human trials. | See the evidence → |